Stocks / NASDAQ / Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

Industry:   Health Care - Biotechnology: In Vitro & In Vivo Diagnostic Substances Stock Symbol:   NTLA - NASDAQ Animal Usage:   Animal Testing

Our Opinion

Intellia Therapeutics, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.

“We have demonstrated substantial progress in our research, including being the first company to present data showing high levels of in vivo editing in animal models using systemic lipid nanoparticles to deliver CRISPR/Cas9 components,” said Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, Intellia Therapeutics. Read the following article

Company Description

Intellia Therapeutics, Inc. engages in the development of proprietary, potentially curative therapeutics. It provides scientific expertise, clinical development and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA. [Source: MarketWatch]

Company Website: http://www.intelliatx.com

Contact:   http://www.intelliatx.com/contact; IR: IRcontact@intelliatx.com;